Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Burn Rate (Quarterly)
Click drug data to see upcoming trial info and prior data
Drug | Disease
Stage | Exp Date
See What The Community Is Saying - Click To See Full Post